English

Pulse Biosciences, Inc.

EDGAR

PLSE Current report (8-K) · filed 2026-10-14

Annual consolidated revenue for 2025: about USD 350K, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

434 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 434000 USD Source

Operating margin

-5,823.04%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -25272000 USD Source
Revenue: 434000 USD Source

Operating cash flow

-18.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -33304000 USD Source
Operating Cash Flow: -14595000 USD Source

Free cash flow

-18.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -33304000 USD Source
Operating Cash Flow: -14595000 USD Source
Capital Expenditure: 123000 USD Source
Capital Expenditure: 33000 USD Source

Cash and cash equivalents: 102 million USD 2026-06-30 Source
Exact value

101600000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 70.8 million shares 2026-06-30 Source
Exact value

70799962 shares

Reported share-count change

5.23% · 3.52 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

67278000 shares · 2025-06-30· Source
70799962 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 5 of 11 periods available· newest 2025-12-31
Total liabilities: 5 of 11 periods available· newest 2025-12-31
Current assets: 5 of 11 periods available· newest 2025-12-31
Current liabilities: 5 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 350,000

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 350,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

350000 − 0 = 350000 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
350000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Year-over-year change in Revenue: 350000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 350000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#816258 Filing: 000143774926004724 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#817006 Filing: 000143774926004724
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 19.2 million

Prior period

−USD 53.59 million

2024-01-01 – 2024-12-31
Current period

−USD 72.78 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-72781000 − -53585000 = -19196000 USD

-53585000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-72781000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Year-over-year change in Net income: -19196000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -72781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#913814 Filing: 000143774926004724 Input fundies:NetIncome: -53585000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#914498 Filing: 000143774926004724
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 17.78 million

Prior period

−USD 36.34 million

2024-01-01 – 2024-12-31
Current period

−USD 54.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-54122000 − -36343000 = -17779000 USD

-36343000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-54122000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Year-over-year change in Operating cash flow: -17779000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -54122000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#939169 Filing: 000143774926004724 Input fundies:OperatingCashFlow: -36343000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#939986 Filing: 000143774926004724
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+152%

Prior period

USD 125,000

2024-01-01 – 2024-12-31
Current period

USD 315,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

315000 − 125000 = 190000 USD

125000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
315000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Year-over-year change in Capital expenditure: 190000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 315000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#943327 Filing: 000143774926004724 Input fundies:CapitalExpenditure: 125000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#944015 Filing: 000143774926004724
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 350,000 100% of revenue
Cost of revenue USD 539,000 154% of revenue
Operating expenses USD 76.75 million 21,929% of revenue
Operating income −USD 76.94 million −21,983% of revenue
Tax, interest and other Derived −USD 4.16 million −1,188% of revenue
Net income −USD 72.78 million −20,795% of revenue

Cash

Operating cash flow −USD 54.12 million −15,463% of revenue
Capital expenditure USD 315,000 90% of revenue
Free cash flow Derived −USD 54.44 million −15,553% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 4,544% of revenue.
2022 Operating loss: operating costs were 8,394% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Operating loss: operating costs were 22,083% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	0	49965000 Derived	-49965000	-114000 Derived	-49851000	-35806000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -49965000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -49851000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -35365000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 441000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1418000	64432000 Derived	-63014000	646000 Derived	-63660000	-54534000 Derived	Source 2021-01-01 – 2021-12-31: 1418000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -63014000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -63660000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -54097000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 437000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	700000	58757000 Derived	-58057000	448000 Derived	-58505000	-47414000 Derived	Source 2022-01-01 – 2022-12-31: 700000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -58057000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -58505000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -47013000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 401000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	43574000 Derived	-43574000	-1364000 Derived	-42210000	-33162000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -43574000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -42210000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -33041000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 121000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	56257000 Derived	-56257000	-2672000 Derived	-53585000	-36468000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -56257000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -53585000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -36343000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 125000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	350000	77289000 Derived	-76939000	-4158000 Derived	-72781000	-54437000 Derived	Source 2025-01-01 – 2025-12-31: 350000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -76939000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -72781000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -54122000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 315000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 350K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	1418000	Revenue: 1418000 Open source
20222022-12-31	Revenue	700000	Revenue: 700000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source
20252025-12-31	Revenue	350000	Revenue: 350000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 1418000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	-50.6%	Revenue: 700000 Open source Revenue: 1418000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 700000 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 350000 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -21,982.6% 2025

Net margin -20,794.6% 2025

Free cash flow margin -15,553.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -49965000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-4,443.9%	Operating Income: -63014000 Open source Revenue: 1418000 Open source
20222022-12-31	Operating margin	-8,293.9%	Operating Income: -58057000 Open source Revenue: 700000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -43574000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -56257000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	-21,982.6%	Operating Income: -76939000 Open source Revenue: 350000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -49851000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-4,489.4%	Net Income: -63660000 Open source Revenue: 1418000 Open source
20222022-12-31	Net margin	-8,357.9%	Net Income: -58505000 Open source Revenue: 700000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -42210000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -53585000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	-20,794.6%	Net Income: -72781000 Open source Revenue: 350000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -35365000 Open source Capital Expenditure: 441000 Open source
20212021-12-31	Free cash flow margin	-3,845.8%	Revenue: 1418000 Open source Operating Cash Flow: -54097000 Open source Capital Expenditure: 437000 Open source
20222022-12-31	Free cash flow margin	-6,773.4%	Revenue: 700000 Open source Operating Cash Flow: -47013000 Open source Capital Expenditure: 401000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -33041000 Open source Capital Expenditure: 121000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -36343000 Open source Capital Expenditure: 125000 Open source
20252025-12-31	Free cash flow margin	-15,553.4%	Revenue: 350000 Open source Operating Cash Flow: -54122000 Open source Capital Expenditure: 315000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -54.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-35365000	Operating Cash Flow: -35365000 Open source
20212021-12-31	Operating cash flow	-54097000	Operating Cash Flow: -54097000 Open source
20222022-12-31	Operating cash flow	-47013000	Operating Cash Flow: -47013000 Open source
20232023-12-31	Operating cash flow	-33041000	Operating Cash Flow: -33041000 Open source
20242024-12-31	Operating cash flow	-36343000	Operating Cash Flow: -36343000 Open source
20252025-12-31	Operating cash flow	-54122000	Operating Cash Flow: -54122000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -54.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-35806000	Operating Cash Flow: -35365000 Open source Capital Expenditure: 441000 Open source
20212021-12-31	Free cash flow	-54534000	Operating Cash Flow: -54097000 Open source Capital Expenditure: 437000 Open source
20222022-12-31	Free cash flow	-47414000	Operating Cash Flow: -47013000 Open source Capital Expenditure: 401000 Open source
20232023-12-31	Free cash flow	-33162000	Operating Cash Flow: -33041000 Open source Capital Expenditure: 121000 Open source
20242024-12-31	Free cash flow	-36468000	Operating Cash Flow: -36343000 Open source Capital Expenditure: 125000 Open source
20252025-12-31	Free cash flow	-54437000	Operating Cash Flow: -54122000 Open source Capital Expenditure: 315000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

14.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Liabilities / assets	Not reported	No source recorded
20212021-12-31	Liabilities / assets	25%	Total Liabilities: 14794000 Open source Total Assets: 59154000 Open source
20222022-12-31	Liabilities / assets	102.9%	Total Liabilities: 80125000 Open source Total Assets: 77877000 Open source
20232023-12-31	Liabilities / assets	25%	Total Liabilities: 14794000 Open source Total Assets: 59154000 Open source
20242024-12-31	Liabilities / assets	13.3%	Total Liabilities: 17598000 Open source Total Assets: 132460000 Open source
20252025-12-31	Liabilities / assets	14.7%	Total Liabilities: 13883000 Open source Total Assets: 94539000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.53× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2020-12-31	Current assets / current liabilities	Not reported	No source recorded
20212021-12-31	Current assets / current liabilities	6.76×	Current Assets: 45328000 Open source Current Liabilities: 6708000 Open source
20222022-12-31	Current assets / current liabilities	10.39×	Current Assets: 62147000 Open source Current Liabilities: 5981000 Open source
20232023-12-31	Current assets / current liabilities	6.76×	Current Assets: 45328000 Open source Current Liabilities: 6708000 Open source
20242024-12-31	Current assets / current liabilities	11.88×	Current Assets: 119449000 Open source Current Liabilities: 10055000 Open source
20252025-12-31	Current assets / current liabilities	10.53×	Current Assets: 83421000 Open source Current Liabilities: 7923000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 49.85 million Exact value Exact value: -49851000 USD 2020-01-01 – 2020-12-31: -49851000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pulse Biosciences, Inc. · 2020-12-31 Pulse Biosciences, Inc. (edgar:1625101) Net Income: -49851000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49851000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#922552 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.	−USD 35.37 million Exact value Exact value: -35365000 USD 2020-01-01 – 2020-12-31: -35365000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pulse Biosciences, Inc. · 2020-12-31 Pulse Biosciences, Inc. (edgar:1625101) Operating Cash Flow: -35365000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35365000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#969611 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.	USD 441,000 Exact value Exact value: 441000 USD 2020-01-01 – 2020-12-31: 441000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pulse Biosciences, Inc. · 2020-12-31 Pulse Biosciences, Inc. (edgar:1625101) Capital Expenditure: 441000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 441000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#973048 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.	−USD 35.81 million Calculation and evidence -35365000 − 441000 USD Exact free cash flow: -35806000 USD 2020-01-01 – 2020-12-31: -35365000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 441000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pulse Biosciences, Inc. · 2020-12-31 Pulse Biosciences, Inc. (edgar:1625101) Free cash flow: -35806000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35365000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#969611 Filing: 000143774923008846 Input fundies:CapitalExpenditure: 441000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#973048 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 63.66 million Exact value Exact value: -63660000 USD 2021-01-01 – 2021-12-31: -63660000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pulse Biosciences, Inc. · 2021-12-31 Pulse Biosciences, Inc. (edgar:1625101) Net Income: -63660000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -63660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#921947 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.	−USD 54.1 million Exact value Exact value: -54097000 USD 2021-01-01 – 2021-12-31: -54097000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pulse Biosciences, Inc. · 2021-12-31 Pulse Biosciences, Inc. (edgar:1625101) Operating Cash Flow: -54097000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54097000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#968873 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.	USD 437,000 Exact value Exact value: 437000 USD 2021-01-01 – 2021-12-31: 437000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pulse Biosciences, Inc. · 2021-12-31 Pulse Biosciences, Inc. (edgar:1625101) Capital Expenditure: 437000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 437000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#972439 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.	−USD 54.53 million Calculation and evidence -54097000 − 437000 USD Exact free cash flow: -54534000 USD 2021-01-01 – 2021-12-31: -54097000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 437000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pulse Biosciences, Inc. · 2021-12-31 Pulse Biosciences, Inc. (edgar:1625101) Free cash flow: -54534000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54097000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#968873 Filing: 000143774923008846 Input fundies:CapitalExpenditure: 437000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774923008846/plse20221231_10k.htm#972439 Filing: 000143774923008846 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 58.51 million Exact value Exact value: -58505000 USD 2022-01-01 – 2022-12-31: -58505000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pulse Biosciences, Inc. · 2022-12-31 Pulse Biosciences, Inc. (edgar:1625101) Net Income: -58505000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58505000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009815/plse20231231_10k.htm#909501 Filing: 000143774924009815 The citation records this snapshot. The page link may show a newer release later.	−USD 47.01 million Exact value Exact value: -47013000 USD 2022-01-01 – 2022-12-31: -47013000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pulse Biosciences, Inc. · 2022-12-31 Pulse Biosciences, Inc. (edgar:1625101) Operating Cash Flow: -47013000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47013000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009815/plse20231231_10k.htm#943025 Filing: 000143774924009815 The citation records this snapshot. The page link may show a newer release later.	USD 401,000 Exact value Exact value: 401000 USD 2022-01-01 – 2022-12-31: 401000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pulse Biosciences, Inc. · 2022-12-31 Pulse Biosciences, Inc. (edgar:1625101) Capital Expenditure: 401000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 401000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009815/plse20231231_10k.htm#946322 Filing: 000143774924009815 The citation records this snapshot. The page link may show a newer release later.	−USD 47.41 million Calculation and evidence -47013000 − 401000 USD Exact free cash flow: -47414000 USD 2022-01-01 – 2022-12-31: -47013000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 401000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pulse Biosciences, Inc. · 2022-12-31 Pulse Biosciences, Inc. (edgar:1625101) Free cash flow: -47414000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47013000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009815/plse20231231_10k.htm#943025 Filing: 000143774924009815 Input fundies:CapitalExpenditure: 401000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774924009815/plse20231231_10k.htm#946322 Filing: 000143774924009815 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 42.21 million Exact value Exact value: -42210000 USD 2023-01-01 – 2023-12-31: -42210000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pulse Biosciences, Inc. · 2023-12-31 Pulse Biosciences, Inc. (edgar:1625101) Net Income: -42210000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42210000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009932/plse20241231_10k.htm#971622 Filing: 000143774925009932 The citation records this snapshot. The page link may show a newer release later.	−USD 33.04 million Exact value Exact value: -33041000 USD 2023-01-01 – 2023-12-31: -33041000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pulse Biosciences, Inc. · 2023-12-31 Pulse Biosciences, Inc. (edgar:1625101) Operating Cash Flow: -33041000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33041000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009932/plse20241231_10k.htm#996795 Filing: 000143774925009932 The citation records this snapshot. The page link may show a newer release later.	USD 121,000 Exact value Exact value: 121000 USD 2023-01-01 – 2023-12-31: 121000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pulse Biosciences, Inc. · 2023-12-31 Pulse Biosciences, Inc. (edgar:1625101) Capital Expenditure: 121000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 121000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009932/plse20241231_10k.htm#999879 Filing: 000143774925009932 The citation records this snapshot. The page link may show a newer release later.	−USD 33.16 million Calculation and evidence -33041000 − 121000 USD Exact free cash flow: -33162000 USD 2023-01-01 – 2023-12-31: -33041000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 121000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pulse Biosciences, Inc. · 2023-12-31 Pulse Biosciences, Inc. (edgar:1625101) Free cash flow: -33162000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33041000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009932/plse20241231_10k.htm#996795 Filing: 000143774925009932 Input fundies:CapitalExpenditure: 121000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009932/plse20241231_10k.htm#999879 Filing: 000143774925009932 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 53.59 million Exact value Exact value: -53585000 USD 2024-01-01 – 2024-12-31: -53585000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pulse Biosciences, Inc. · 2024-12-31 Pulse Biosciences, Inc. (edgar:1625101) Net Income: -53585000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -53585000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#914498 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.	−USD 36.34 million Exact value Exact value: -36343000 USD 2024-01-01 – 2024-12-31: -36343000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pulse Biosciences, Inc. · 2024-12-31 Pulse Biosciences, Inc. (edgar:1625101) Operating Cash Flow: -36343000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36343000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#939986 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.	USD 125,000 Exact value Exact value: 125000 USD 2024-01-01 – 2024-12-31: 125000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pulse Biosciences, Inc. · 2024-12-31 Pulse Biosciences, Inc. (edgar:1625101) Capital Expenditure: 125000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 125000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#944015 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.	−USD 36.47 million Calculation and evidence -36343000 − 125000 USD Exact free cash flow: -36468000 USD 2024-01-01 – 2024-12-31: -36343000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 125000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pulse Biosciences, Inc. · 2024-12-31 Pulse Biosciences, Inc. (edgar:1625101) Free cash flow: -36468000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36343000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#939986 Filing: 000143774926004724 Input fundies:CapitalExpenditure: 125000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#944015 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 72.78 million Exact value Exact value: -72781000 USD 2025-01-01 – 2025-12-31: -72781000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Net Income: -72781000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -72781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#913814 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.	−USD 54.12 million Exact value Exact value: -54122000 USD 2025-01-01 – 2025-12-31: -54122000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Operating Cash Flow: -54122000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54122000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#939169 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.	USD 315,000 Exact value Exact value: 315000 USD 2025-01-01 – 2025-12-31: 315000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Capital Expenditure: 315000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 315000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#943327 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.	−USD 54.44 million Calculation and evidence -54122000 − 315000 USD Exact free cash flow: -54437000 USD 2025-01-01 – 2025-12-31: -54122000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 315000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Pulse Biosciences, Inc. · 2025-12-31 Pulse Biosciences, Inc. (edgar:1625101) Free cash flow: -54437000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:42:24Z Snapshot: 79fa372638030be13240409c896672b9f1a75521a7cc5ef77c922fa592557ac0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1625101?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54122000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#939169 Filing: 000143774926004724 Input fundies:CapitalExpenditure: 315000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1625101/000143774926004724/plse20251231_10k.htm#943327 Filing: 000143774926004724 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

92 filings · 2,834 latest values · 2,834 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001625101, 1625101, PLSE, edgar:1625101, plse

Also known as Electroblate, Inc., PULSE BIOSCIENCES, INC., Pulse Biosciences, Inc., Pulse Biosciences, Inc.

Pulse Biosciences, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation